EVAXION_BLACK_RGB.jpg
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
November 17, 2022 06:59 ET | Evaxion Biotech
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
EVAXION_BLACK_RGB.jpg
Evaxion Announces Third Quarter 2022 Financial Results and Business Update
November 14, 2022 07:13 ET | Evaxion Biotech
Per Norlén, M.D., PhD. joined Evaxion as Chief Executive Officer in October Enrollment of the first patient in our global Phase 2b clinical trial of EVX-01 Increased strategic focus on clinical lead...
EVAXION_BLACK_RGB.jpg
Evaxion CEO kommentiert strategische Ausrichtung
November 14, 2022 05:31 ET | Evaxion Biotech
KOPENHAGEN, Dänemark, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion" oder das „Unternehmen“), ein Biotechnologieunternehmen im klinischen Stadium, das sich auf...
EVAXION_BLACK_RGB.jpg
Le PDG d'Evaxion commente l'orientation stratégique du groupe
November 14, 2022 05:31 ET | Evaxion Biotech
COPENHAGUE, Danemark, 14 nov. 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie clinique spécialisée dans le développement...
EVAXION_BLACK_RGB.jpg
Evaxion CEO comments on strategic focus
November 10, 2022 04:10 ET | Evaxion Biotech
COPENHAGEN, Denmark, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
EVAXION_BLACK_RGB.jpg
Evaxion begrüßt Per Norlén als neuen CEO
October 06, 2022 07:58 ET | Evaxion Biotech
KOPENHAGEN, Dänemark, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein Biotechnologieunternehmen in der klinischen Phase, das sich...
EVAXION_BLACK_RGB.jpg
Evaxion accueille Per Norlén au poste de nouveau PDG
October 06, 2022 07:58 ET | Evaxion Biotech
COPENHAGUE, Danemark, 06 oct. 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie au stade clinique spécialisée dans le...
EVAXION_BLACK_RGB.jpg
Evaxion welcomes Per Norlén as new CEO.
October 05, 2022 08:32 ET | Evaxion Biotech
COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
EVAXION_LOCKUP_DEEPBLUE_RGB[87].png
Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy
September 21, 2022 05:45 ET | Evaxion Biotech
COPENHAGEN, Denmark, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
evaxion-biotech-logo1big.png
Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School
September 06, 2022 07:02 ET | Evaxion Biotech
COPENHAGEN, Denmark, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), announced today that the Company, in collaboration with UMass Chan Medical...